MYL9 and posterior cortical atrophy: Then, for 476 PCa patients with data on PFS, a Cox risk proportional regression model was created (Figure 6C): The risk score was calculated as follows: [expression level of CD38 × 0.774989] + [expression level of TPM2 × 0.882436] + [expression level of MT1X × 0.880267] + [expression level of CRISP3 × 0.929862] + [expression level of MYL9 × 1.373418] + [expression level of MYLK × 0.692560].